Objective, reproducible, and trustworthy data in clinical trials with imaging endpoints

Dr. Anthony Tolcher, medical oncologist and CEO of NEXT Oncology, spoke to us about objectivity as one of the biggest challenges in clinical trials and how a software solution for tumor assessment can improve the quality and reproducibility of data, all while saving time.

Moreover, such software solutions are a key aspect for the approval of novel drugs based on small sample size – like for example targeted or tissue agnostic medicine, as a significant advance for precision therapies. Dr. Tolcher describes how mint Lesion™ assists in generating trustworthy data, “so that [one] can ensure that the drugs that are getting approved really do work.”

Click here or on the image above to watch the full video on YouTube.

Structured Reporting Clinical Trials Standardized Reading Procedures Therapy Response Assessment Video

Related Resources

Related Resources

Image of a patient getting an MRI scan, signifying how RACOON projects in Germany show how imaging, structured reporting, and AI jointly advance clinical research.

RACOON – Imaging, Data & Collaboration for Better Decisions

Modern radiology faces a central question: how can imaging and clinical data be combined in a way that leads to more precise diagnoses,…

Interview with Prof. Timm Denecke about the RACOON-MARDER project and AI-powered early detection of liver cancer using MRI

Rethinking Early Detection: How RACOON-MARDER Aims to Spot Liver Cancer Sooner

Hepatocellular carcinoma (HCC) is often diagnosed too late, limiting treatment options and survival. The RACOON-MARDER project aims to change that. By…

mint Lesion's Research Suite: advanced imaging research platform designed to support

mint Lesion Research Suite: The Flexible Imaging Research Platform Built for Scalable, Single- and Multi-Center Studies

mint Lesion's Research Suite is an advanced imaging research platform designed to support academic teams in streamlining and scaling their imaging…